Literature DB >> 28078122

Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer.

Makoto Kadokura1, Yasuaki Ishida1, Akihisa Tatsumi1, Ei Takahashi2, Hiroko Shindo2, Fumitake Amemiya1, Shinichi Takano2, Mitsuharu Fukasawa2, Tadashi Sato2, Nobuyuki Enomoto2.   

Abstract

BACKGROUND: The usefulness of various prognostic factors for pancreatic cancer (PC) has been reported, but the number of elderly patients in these studies is disproportionately fewer compared with those in everyday practice. The purpose of this study was to investigate the prognostic factors for unresectable PC in elderly patients.
METHODS: We retrospectively analyzed 67 elderly (age ≥75 years) patients with unresectable PC who underwent chemotherapy between January 2006 and December 2014 at our hospital. Univariate and multivariate Cox regression models were applied to investigate independent prognostic factors.
RESULTS: Multivariate analysis revealed that an increased neutrophil-lymphocyte ratio (NLR) [hazard ratio (HR) 1.91, P=0.03] and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 (HR 2.74, P=0.01) were independent negative prognostic factors.
CONCLUSIONS: The two prognostic factors identified herein are useful in the identification of patients with a poor prognosis and subsequent administration of supportive care alone, which may help avoid the unnecessary adverse effects and complications of systemic chemotherapy.

Entities:  

Keywords:  Pancreatic cancer (PC); elderly patient; neutrophil-lymphocyte ratio (NLR); prognostic factor

Year:  2016        PMID: 28078122      PMCID: PMC5177571          DOI: 10.21037/jgo.2016.06.06

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  36 in total

1.  Performance status is an important prognostic factor in second line treatment of pancreaticobiliary adenocarcinoma.

Authors:  Bulent Erdogan; Esma Turkmen; Sernaz Uzunoglu; Ozgur Tanriverdi; Irfan Cicin
Journal:  Hepatogastroenterology       Date:  2013-09

Review 2.  Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review.

Authors:  Jawad Ahmad; Nathan Grimes; Shahid Farid; Gareth Morris-Stiff
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2014-10

3.  Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Authors:  Josep Tabernero; E Gabriela Chiorean; Jeffrey R Infante; Sunil R Hingorani; Vinod Ganju; Colin Weekes; Werner Scheithauer; Ramesh K Ramanathan; David Goldstein; Darryl N Penenberg; Alfredo Romano; Stefano Ferrara; Daniel D Von Hoff
Journal:  Oncologist       Date:  2015-01-12

4.  Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model.

Authors:  Jadwiga Jablonska; Sara Leschner; Kathrin Westphal; Stefan Lienenklaus; Siegfried Weiss
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

5.  Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.

Authors:  Qiwen Ben; Wei An; Lifu Wang; Weiyi Wang; Lei Yu; Yaozong Yuan
Journal:  Pancreas       Date:  2015-04       Impact factor: 3.327

6.  Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.

Authors:  Kyu-Hyoung Lim; Tae-Yong Kim; Kyung-Hun Lee; Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang
Journal:  Cancer Chemother Pharmacol       Date:  2011-02-17       Impact factor: 3.333

7.  Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma.

Authors:  Faruk Tas; Senem Karabulut; Elif Bilgin; Leyla Kılıc; Rumeysa Ciftci; Derya Duranyildiz
Journal:  J Gastrointest Cancer       Date:  2013-12

8.  Choice of cancer therapy varies with age of patient.

Authors:  J Samet; W C Hunt; C Key; C G Humble; J S Goodwin
Journal:  JAMA       Date:  1986-06-27       Impact factor: 56.272

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival.

Authors:  Faruk Tas; Fatma Sen; Serkan Keskin; Leyla Kilic; Ibrahim Yildiz
Journal:  Mol Clin Oncol       Date:  2013-05-23
View more
  4 in total

1.  The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients.

Authors:  Matteo Piciucchi; Serena Stigliano; Livia Archibugi; Giulia Zerboni; Marianna Signoretti; Viola Barucca; Roberto Valente; Gianfranco Delle Fave; Gabriele Capurso
Journal:  Int J Mol Sci       Date:  2017-03-29       Impact factor: 5.923

2.  The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.

Authors:  Byung Min Lee; Seung Yeun Chung; Jee Suk Chang; Kyong Joo Lee; Jinsil Seong
Journal:  Gut Liver       Date:  2018-05-15       Impact factor: 4.519

3.  C-reactive protein/albumin ratio predicts survival after curative surgery in elderly patients with colorectal cancer.

Authors:  Koki Tamai; Shu Okamura; Shunichiro Makino; Noriyuki Yamamura; Nariaki Fukuchi; Chikara Ebisui; Akira Inoue; Masahiko Yano
Journal:  Updates Surg       Date:  2021-03-06

4.  PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma.

Authors:  Lin Zhou; Jing Wang; Shao-Cheng Lyu; Li-Chao Pan; Xian-Jie Shi; Guo-Sheng Du; Qiang He
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.